Herein, we show a selective action of WIN 55-212.2 mesylate, a synthetic cannabinoid with affinity for CB1 and CB2 higher than THC, on prostate cancer cell lines without affecting healthy counterpart. The gene discussed is CNR1; the disease is prostate cancer.